Upload
PPT-Figure 2 Figure 2. SARS-CoV-2 S antibody seroprevalence, titers, and vaccine doses of

PPT-Figure 2 Figure 2. SARS-CoV-2 S antibody seroprevalence, titers, and vaccine doses of

Author : abigail | Published Date : 2024-09-06

Nilles EJ de St Aubin M Dumas D Duke W Etienne M Abdalla G et al Monitoring Temporal Changes in SARSCoV2 Spike Antibody Levels and VariantSpecific Risk for Infection

amp age years smoothed age amp smoothed years antibody gray dots line participants study ages shading loess percentage dot

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Figure 2 Figure 2. SARS-CoV-2 S antibody..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Figure 2 Figure 2. SARS-CoV-2 S antibody seroprevalence, titers, and vaccine doses of: Transcript

Download Document

Here is the link to download the presentation.
"Figure 2 Figure 2. SARS-CoV-2 S antibody seroprevalence, titers, and vaccine doses of"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents

Laboratory Serology for SARS

Laboratory Serology for SARS
Figure Figure. Seroprevalence of neutralizing antibody (titers >16) to

Figure Figure. Seroprevalence of neutralizing antibody (titers >16) to
Figure 1 Figure 1. A) Age-dependent herpesvirus 8 (HHV-8) seroprevalence rates

Figure 1 Figure 1. A) Age-dependent herpesvirus 8 (HHV-8) seroprevalence rates
Figure 3 Figure 3. . Age distribution of children with measles reported in Malawi, 2010.

Figure 3 Figure 3. . Age distribution of children with measles reported in Malawi, 2010.
Figure 4 Figure 4. A. Plaque-reduction neutralizing antibody titers (PRNT) according

Figure 4 Figure 4. A. Plaque-reduction neutralizing antibody titers (PRNT) according
Figure 2 Figure 2. Results from a serologic study of the 2007 epizootic wave

Figure 2 Figure 2. Results from a serologic study of the 2007 epizootic wave
Figure 1 Figure 1. Serum antibodies (Abs) in patients infected with influenza A(H7N9)

Figure 1 Figure 1. Serum antibodies (Abs) in patients infected with influenza A(H7N9)
Figure Figure. Results of hemagglutination-inhibition (HI) testing of modified vaccinia

Figure Figure. Results of hemagglutination-inhibition (HI) testing of modified vaccinia
Figure 2 Figure 2. . Correlation of neutralizing antibody titers measured by plaque reduction

Figure 2 Figure 2. . Correlation of neutralizing antibody titers measured by plaque reduction
Figure S1. Distribution of SERASCA® test titers per farm (n=65 farms, finishers)

Figure S1. Distribution of SERASCA® test titers per farm (n=65 farms, finishers)
Figure Figure. Schematic illustration of the epidemiologic relationships between

Figure Figure. Schematic illustration of the epidemiologic relationships between
Figure 1 Figure 1. Western blot antibody reactivity of chicken sera to endogenous

Figure 1 Figure 1. Western blot antibody reactivity of chicken sera to endogenous
Figure 2 Figure 2. Effect of commercially available alcohols in inactivating SARS-CoV-2.

Figure 2 Figure 2. Effect of commercially available alcohols in inactivating SARS-CoV-2.